Business Context and Reporting Period
Company: NeoGenomics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 15, 2026
Event: Commencement of a proposed offering of convertible senior notes due 2032 to qualified institutional buyers pursuant to Rule 144A.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on the announcement of a capital raising event.
Material Changes
The material change reported is the initiation of the "Convertible Notes Offering." The company has begun offering convertible senior notes due 2032. No comparative financial data or changes in operating metrics are disclosed in this document.
Guidance, Outlook, and Risks
- Offering Details: The offering consists of convertible senior notes due 2032.
- Target Investors: Persons reasonably believed to be qualified institutional buyers.
- Legal Disclaimer: The filing and its exhibits do not constitute an offer to sell or a solicitation of an offer to buy securities in any jurisdiction where such activity would be unlawful.
- Management Commentary: No specific commentary on future performance or strategic outlook is included in the text of this 8-K, other than the execution of the offering.
Investor Verification Checklist
- Verify the final terms of the Convertible Notes Offering (interest rate, conversion price, and total principal amount) in the accompanying press release (Exhibit 99.1) or subsequent prospectus supplement.
- Confirm the use of proceeds from the offering once disclosed.
- Monitor for any updates regarding the completion or termination of the offering.
- Review the company's most recent 10-K or 10-Q for baseline debt levels and liquidity status prior to this new issuance.